BRPI0713330A2 - adjuvantes e métodos de uso - Google Patents

adjuvantes e métodos de uso Download PDF

Info

Publication number
BRPI0713330A2
BRPI0713330A2 BRPI0713330-8A BRPI0713330A BRPI0713330A2 BR PI0713330 A2 BRPI0713330 A2 BR PI0713330A2 BR PI0713330 A BRPI0713330 A BR PI0713330A BR PI0713330 A2 BRPI0713330 A2 BR PI0713330A2
Authority
BR
Brazil
Prior art keywords
methods
adjuvants
nkt cell
agonist compounds
cell agonist
Prior art date
Application number
BRPI0713330-8A
Other languages
English (en)
Inventor
Teyton Luc
Bendelac Albert
B. Savage Paul
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of BRPI0713330A2 publication Critical patent/BRPI0713330A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

ADJUVANTES E MéTODOS DE USO. Esta invenção fornece composições que compreendem compostos agonistas de células NKT e um veículo fisiologicamente aceitável. Métodos para estimular uma célula NKT e intensificar uma resposta imune também são descritos. São fornecidas ainda preparações de vacinas que compreendem compostos agonistas de células NKT.
BRPI0713330-8A 2006-06-30 2007-06-29 adjuvantes e métodos de uso BRPI0713330A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80633006P 2006-06-30 2006-06-30
US60/806.330 2006-06-30
PCT/US2007/072451 WO2008005824A1 (en) 2006-06-30 2007-06-29 Adjuvants and methods of use

Publications (1)

Publication Number Publication Date
BRPI0713330A2 true BRPI0713330A2 (pt) 2012-04-17

Family

ID=38894900

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0713330-8A BRPI0713330A2 (pt) 2006-06-30 2007-06-29 adjuvantes e métodos de uso

Country Status (8)

Country Link
US (2) US7794722B2 (pt)
EP (1) EP2040541B1 (pt)
JP (1) JP5564672B2 (pt)
AU (1) AU2007269299B2 (pt)
BR (1) BRPI0713330A2 (pt)
CA (1) CA2655947C (pt)
WO (1) WO2008005824A1 (pt)
ZA (1) ZA200900203B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
PL1848813T3 (pl) 2005-01-28 2013-09-30 Univ Brigham Young Aktywacja glikolipidem bakteryjnym komórek NKT podlegających restrykcji CD1d
BRPI0710668A2 (pt) * 2006-04-07 2011-08-16 Scripps Res Insittute alfa-galactosil ceramidas modificadas para marcar e estimular células t matadoras naturais
IL178821A0 (en) * 2006-05-25 2007-07-04 Ilan Yaron Direct and indirect modulation of composition and structure of cell membrane by ??-glycolipids
BRPI0713330A2 (pt) 2006-06-30 2012-04-17 The Scripps Research Institute adjuvantes e métodos de uso
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2058011A1 (en) 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
US8211861B2 (en) 2007-12-05 2012-07-03 Wittycell Compositions for and methods of enhancing the immune response to antigens
JP2011524375A (ja) 2008-06-16 2011-09-01 アカデミア シニカ ＧｌｏｂｏＨおよびＳＳＥＡ３に特異的な免疫反応を誘起する組成物および癌治療におけるその使用
WO2010040710A1 (en) * 2008-10-08 2010-04-15 Wittycell Vaccine composition for use against influenza
LT3193923T (lt) 2014-07-24 2019-12-10 Litevax B V Adjuvantai
TWI745275B (zh) * 2014-09-08 2021-11-11 中央研究院 使用醣脂激活人類ｉＮＫＴ細胞
WO2019190986A1 (en) * 2018-03-26 2019-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 3-o-sulfo-galactosylceramide analogs as activators of type ii nkt cells and uses thereof
EP3925963A1 (en) * 2020-06-18 2021-12-22 Helmholtz-Zentrum für Infektionsforschung GmbH Phytosphingosine derivatives as adjuvants in immune stimulation

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146810A3 (de) * 1983-12-05 1987-05-13 Solco Basel AG Verfahren zur Herstellung von Sphingosinderivaten
DE3852526D1 (de) * 1987-06-26 1995-02-02 Solco Basel Ag Neue pharmazeutische Präparate sowie neue Lactosylverbindungen und ihre Herstellung.
US5242800A (en) * 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
DK84691D0 (da) 1991-05-07 1991-05-07 Karsten Buschard Visse glycolipider og specifikke catchere for disse til anvendelse ved profylaxe eller terapi af diabetes, og/eller dermed forbundne komplikationer samt anvendelse af saadanne glycolipider til detektion af oe-celle-antistoffer (ica) i et individ og anvendelse af saadanne catchere til detektion af langerhans-oe-celler i pancreas-praeparater
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (pt) * 1992-07-16 1995-11-01 Kirin Brewery
EP0666268B1 (en) * 1992-10-22 2000-04-19 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
KR100281265B1 (ko) * 1993-04-15 2001-02-01 마나배 게이사꾸 신규한 스핀고당지질 및 그의 사용
RO117533B1 (ro) * 1993-05-14 2002-04-30 Cytel Corp San Diego DERIVATI DE ANALOGI SIALIL LeX INHIBITORI AI ADEZIUNII CELULARE SI COMPOZITIE FARMACEUTICA CU ACESTIA
JPH08109134A (ja) * 1994-10-11 1996-04-30 Sanwa Kagaku Kenkyusho Co Ltd 細胞変成抑制並びに臓器毒性軽減剤
JP3495740B2 (ja) * 1997-04-10 2004-02-09 麒麟麦酒株式会社 α−グリコシルセラミドを含有するＮＫＴ細胞活性化剤
AU2001252599A1 (en) 2000-04-28 2001-11-12 Orient Cancer Therapy Co., Ltd. Remedies for cancer
WO2001098317A2 (en) * 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
WO2003016326A1 (fr) * 2001-08-16 2003-02-27 Daiichi Suntory Pharma Co., Ltd. Glycolipide et agent therapeutique pour maladies auto-immunes le contenant en tant qu'ingredient actif
KR100549866B1 (ko) 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
JPWO2003039568A1 (ja) * 2001-11-06 2005-02-24 株式会社オリエントキャンサーセラピー 抗癌組成物
US7273852B2 (en) * 2002-06-13 2007-09-25 The Research Foundation Of The City University Of New York Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20040171522A1 (en) 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
AU2003225891A1 (en) 2003-03-20 2004-11-19 Brigham Young University 6"-amino-6"-deoxygalactosylceramides
US7645873B2 (en) * 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
EP1686959B1 (en) * 2003-11-14 2009-06-24 HET NEDERLANDS KANKER INSTITUUT (The Netherlands Cancer Institute) Pharmaceutical formulations employing short-chain sphingolipids and their use
PT1767216E (pt) * 2004-06-11 2012-08-27 Riken Fármaco tendo um ligando de células reguladoras contido num lipossoma
KR101377116B1 (ko) 2004-08-27 2014-03-24 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 면역 및 자가면역의 조절제로서의 세라마이드 유도체
JP5005541B2 (ja) * 2004-09-03 2012-08-22 ザ ユニヴァーシティー オヴ シカゴ Ｎｋｔ細胞の活性化方法
EP1833489A4 (en) * 2004-12-28 2011-08-03 Univ Rockefeller GLYCOLIPIDES AND ANALOGUE THEREOF AS ANTIGENS FOR NK-T CELLS
US7551694B2 (en) 2005-01-20 2009-06-23 Marvell World Trade Ltd. Limiter based analog demodulator
PL1848813T3 (pl) 2005-01-28 2013-09-30 Univ Brigham Young Aktywacja glikolipidem bakteryjnym komórek NKT podlegających restrykcji CD1d
US8044029B2 (en) * 2005-09-29 2011-10-25 Torrey Pines Institute For Molecular Studies Sulfatides for treatment of autoimmune disorders
JP5392451B2 (ja) * 2005-12-27 2014-01-22 国立大学法人 琉球大学 抗腫瘍剤及び免疫賦活剤
BRPI0710668A2 (pt) 2006-04-07 2011-08-16 Scripps Res Insittute alfa-galactosil ceramidas modificadas para marcar e estimular células t matadoras naturais
BRPI0713330A2 (pt) 2006-06-30 2012-04-17 The Scripps Research Institute adjuvantes e métodos de uso

Also Published As

Publication number Publication date
JP2009542712A (ja) 2009-12-03
AU2007269299B2 (en) 2013-01-17
AU2007269299A1 (en) 2008-01-10
EP2040541B1 (en) 2016-03-23
AU2007269299A2 (en) 2009-01-29
US20110027323A1 (en) 2011-02-03
ZA200900203B (en) 2013-06-26
EP2040541A4 (en) 2012-08-29
EP2040541A1 (en) 2009-04-01
US7794722B2 (en) 2010-09-14
WO2008005824A1 (en) 2008-01-10
CA2655947A1 (en) 2008-01-10
CA2655947C (en) 2016-08-02
US20080095787A1 (en) 2008-04-24
JP5564672B2 (ja) 2014-07-30
US8932594B2 (en) 2015-01-13

Similar Documents

Publication Publication Date Title
BRPI0713330A2 (pt) adjuvantes e métodos de uso
CR20150088A (es) Anticuerpos anti-notch1 nrr
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
CO6430456A2 (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
ECSP099662A (es) Nuevos Derivados de 3-([1,2,4]triazolo[4,3-a]piridin-7-il)benzamida
UY28342A1 (es) Nuevos compuestos
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
AR057253A1 (es) Anticuerpos anti-ox40l y metodos que los utilizan
BR112012013345A2 (pt) composições orais contendo uma combinação de extratos naturais e métodos relacionados
ECSP10010693A (es) Compuestos pirazólicos 436
GT200900292A (es) "inhibidores de cinasa p70 s6"
BRPI0511133A (pt) uso de galacto-oligossacarìdeos e polifrutose
CR10094A (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
UY32203A (es) Amino pirimidinas y su uso en terapia
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
MX2010007150A (es) Formulaciones del factor de von-willebrand recombinante.
UY31073A1 (es) Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap)
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
ECSP11011344A (es) Nuevos anticuerpos anti-?5?1 y sus usos
NO20070785L (no) Sammensetninger for levering av svaert vannloselige medikamenter.
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
AR059096A1 (es) Anticuerpos anti- efrina -b2 y metodos que usan estos
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso
BRPI0606506A2 (pt) polipeptìdeos de yersinia spp. e métodos de uso
AR072425A1 (es) Uso de nifurtimox para el tratamiento de giardiasis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]